

Curative treatment of AF:

Too far to reach?

Gerhard Hindricks

University of Leipzig
- Heart Center -
Dept. of Electrophysiology



Presenter Disclosure Information


Gerhard Hindricks has received honoraria for lectures from Biosense, St. Jude Medical, Biotronik, Medtronic, Boehringer Ingelheim

Gerhard Hindricks has received research grants from St. Jude Medical, Biotronik, Biosense



Gerhard Hindricks is a member of the Advisory Board / consultant for Biosense, St. Jude Medical, Biotronik, Stereotaxis,

Curative treatment of atrial fibrillation: too far to reach?


The beauty of catheter ablation...



Intraoperative ablation of AF – 10 yr. FU




Intraoperative ablation of AF: 10 yr follow-up



Progression of atrial fibrillation

- Why does AF progress?
- What are the (main) drivers promoting AF progression?
- Can these drivers be modulated by catheter ablation?


'Natural' time course of AF



Progression of atrial fibrillation


- Which mechanisms / factors govern the dynamics of AF progression?
- Are mechanisms / factors the same in all AF patients?

'Natural' time course of AF




Progression of atrial fibrillation

- Which mechanisms / factors govern the dynamics of AF progression?
- Are mechanisms / factors the same in all AF patients?
- Is there a point of no return to SR?



Progression of atrial fibrillation: the concept

- AF begets AF
- AF induced re-modeling
 - electrophysiological properties
 - structural re-modeling
 - atrial fibrosis
- “The more you have... the more you get!”




Progression of atrial fibrillation: the concept

- AF begets AF
- AF induced re-modeling
 - electrophysiological properties
 - structural re-modeling
 - atrial fibrosis
- “The more you have... the more you get!”

hypertension

age LVEF

valvular HD



Progression of atrial fibrillation: the concept

- AF begets AF

AF induces re-modeling


- electrophysiological properties
- structural re-modeling
- atrial fibrosis

- “The more you have... the more you get!”

hypertension

age LVEF

valvular HD



Progression of atrial fibrillation: the concept


- AF begets AF

CURE?

hypertension

age LVEF

valvular HD




Thoughts about “AF begets AF”

- The concept is based on animal experimental studies performed in healthy goats driven to AF by high frequency stimulation.
- The relevance for human AF is not fully established.
- Is atrial re-modeling a consequence of AF.....or is AF a consequence of re-modeling?
- What do we know about the substrate of human AF?
 - data from pathology, imaging, and electrophysiological studies.


The substrate of human AF: pathology

- Expression of major extracellular matrix (collagen I and III, fibronectin protein) in patients with SR, lone AF, and AF plus MVD.
- Left atrial tissue from 118 patients undergoing cardiac surgery.




SR

AF




The substrate of human AF: pathology

- post mortem analysis of fibrosis
- no AF ●, PAF ●, permanent AF ●
- correlation with age



The substrate of human AF: pathology


- Fibrosis and AF type (PAF, permanent AF)



Substrate of human AF

- Significant structural re-modeling, i.e. extensive atrial fibrosis, has been found in lone AF, paroxysmal and persistent AF. However, there seem to be only weak correlations between AF duration and extent of fibrosis.
- Age does not correlate with fibrosis.

Visualisation of fibrosis with DE MRI



Visualisation of fibrosis with DE MRI

Table 3 Distribution in Utah I to IV

	Total (n = 333)	Lone AF (n = 40)	Non-lone AF (n = 293)	<i>P</i> value
Utah I, n (%)	21	4 (10)	17 (5.8)	.298
Utah II, n (%)	141	26 (65)	187 (63.82)	.884
Utah III, n (%)	148	9 (22.5)	67 (22.87)	.959
Utah IV, n (%)	23	1 (2.5)	22 (7.51)	.334

Visualisation of fibrosis with DE MRI

CONCLUSION—The degree of LA structural remodeling as detected using DE-MRI is independent of AF type and associated comorbidities. Selecting appropriate treatment candidates based on the quality and quantity of atrial fibrosis using DE-MRI would improve procedural outcome and avoid unnecessary intervention.


	Total (n = 333)	Lone AF (n = 40)	Non-lone AF (n = 293)	<i>P</i> value
Utah I, n (%)	21	4 (10)	17 (5.8)	.298
Utah II, n (%)	141	26 (65)	187 (63.82)	.884
Utah III, n (%)	148	9 (22.5)	67 (22.87)	.959
Utah IV, n (%)	23	1 (2.5)	22 (7.51)	.334

Substrate of human AF

- Significant structural re-modeling, i.e. extensive atrial fibrosis, has been found in lone AF, paroxysmal and persistent AF. However, there seem to be only weak correlations between AF duration and extent of fibrosis.
- Age does not correlate with fibrosis.
- DE MRI: the extent of fibrosis does not correlate with type of AF and co-morbidities.

Curative treatment of atrial fibrillation: too far to reach?



Substrate analysis: generation of voltage maps





Curative treatment of atrial fibrillation: too far to reach?



Individualized lesion deployment according to fibrosis

Case II




Case III







Electrophysiological studies in lone AF

- 25 pts. with lone AF *without* arrhythmia in the week prior
- compared to 25 patients without AF
- conduction time & velocity, refractory periods, voltage



Electrophysiological studies in lone AF




Conclusions

Patients with paroxysmal lone AF, remote from arrhythmia, demonstrate bi-atrial abnormalities characterized by structural change, conduction abnormalities, and sinus node dysfunction. These factors are likely contributors to the "second factor" that predisposes to the development and progression of AF. (J Am Coll Cardiol 2009;53: 1182-91) © 2009 by the American College of Cardiology Foundation


Is there reversed remodeling after catheter ablation?

- 11 pts. with AF and no apparent structural heart disease were compared to 11 control patients
- Detailed right atrial voltage maps, conduction properties, refractory periods were assessed at baseline and > 6 months after successful AF ablation.
- Mean FU at re-study was 10 ± 13 months


Is there reversed remodeling after catheter ablation?




Is there reversed remodeling after catheter ablation?



Is there reversed remodeling after catheter ablation?



Is there reversed remodeling after catheter ablation?



Substrate of human AF

- Significant structural re-modeling, i.e. extensive atrial fibrosis, has been found in lone AF, paroxysmal and persistent AF. However, there seem to be only weak correlations between AF duration and extent of fibrosis.
- Age does not correlate with fibrosis.
- DE MRI: the extent of fibrosis does not correlate with type of AF and co-morbidities.
- Human EP studies in patients with lone AF clearly show a significant electrophysiological re-modeling even in “early” stage of AF.
- This re-modeling may be irreversible. Moreover, it seems possible that there is substrate progression despite successful ablation.

Final thoughts

- There is growing evidence that the concept of “AF begets AF” may not be fully applicable in human AF.
- Even in early stages of (lone) AF significant re-modeling can be observed.
- It seems to be likely that “second factors”, e.g. fibrosis that promotes AF, are operative in the progression of AF.
- Atrial re-modeling may be irreversible – this should give rise to consider early intervention. However, it is unknown at present whether progression of AF is affected by successful ablation in
 - all patients
 - selected patient populations
 - ...or not at all.

Future perspective

- Longitudinal studies are needed to better understand the “natural” progression of AF in different subset of patients – I believe they are not all the same.
- Non-invasive imaging using MRI seems to be the best approach to systematically generate such data.
- Genetic studies on potential “second factors” may further improve our understanding of AF progression.
- Invasive substrate-based treatment of AF in an MRI environment seems desirable.....and feasible in the near future.